Detalhe da pesquisa
1.
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias.
Br J Haematol
; 199(4): 520-528, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36041779
2.
Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series.
Clin Transplant
; 36(3): e14541, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34797567
3.
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Cancer
; 127(11): 1816-1826, 2021 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33735504
4.
Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(5): 876-883, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31785375
5.
Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(6): 1218-1224, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30708189
6.
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Blood
; 127(21): 2561-8, 2016 05 26.
Artigo
Inglês
| MEDLINE | ID: mdl-26932802
7.
Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports.
Am J Kidney Dis
; 69(6): 858-862, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-28320553
8.
Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 22(6): 1030-1036, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-26899561
9.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Am J Hematol
; 91(4): 400-5, 2016 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-26800393
10.
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
Blood Adv
; 8(9): 2207-2216, 2024 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38429087
11.
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Nat Commun
; 13(1): 4121, 2022 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35840578
12.
Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation.
EJHaem
; 2(2): 276-279, 2021 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35845271
13.
Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
J Immunother Cancer
; 9(7)2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34272304
14.
Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Transplant Cell Ther
; 27(6): 477.e1-477.e7, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33831353
15.
Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.
J Geriatr Oncol
; 12(4): 531-539, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33059999
16.
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Br J Haematol
; 150(4): 428-37, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20618338
17.
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
Blood Adv
; 4(13): 2899-2911, 2020 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32589729
18.
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Nat Commun
; 11(1): 1931, 2020 04 22.
Artigo
Inglês
| MEDLINE | ID: mdl-32321912
19.
Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies.
Patient Educ Couns
; 102(9): 1602-1612, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31076236
20.
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Mol Cancer Ther
; 18(11): 2008-2020, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31434693